✦ LIBER ✦

Fulminant hepatic failure in chronic hepatitis B on withdrawal of corticosteroids, azathioprine and infliximab for Crohn's disease

✍ Scribed by Carmelita Colbert; Arturo Chavarria; Charles Berkelhammer

Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 55 KB
Volume: 13
Category: Article
ISSN: 1078-0998
DOI: 10.1002/ibd.20216

No coin nor oath required. For personal study only.

✦ Synopsis

lymphocytes can be targets for anti-TNF-␣ antibodies. 7 Apoptosis leads to the removal of the dying cell by macrophages in a way that prevents the onset of inflammatory reactions, thus explaining the strong antiinflammatory properties observed and the sustained therapeutic response (far beyond the estimated circulating half-life of the antibody) even after a single dose of infliximab. Maintenance of response could be due to similar effects of infliximab to TH1 CD4-activated tissue or systemic cells and the subsequent decrease of antiplatelet antibody production from B-lymphocytes.

📜 SIMILAR VOLUMES

Lamivudine resistance and exacerbation o

Lamivudine resistance and exacerbation of hepatitis B in infliximab-treated Crohn's disease patient

✍ Maria Esteve; Carme Loras; Ferran González-Huix 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB 👁 1 views

2004 we reported 3 cases of chronic hepatitis B in Crohn's disease (CD) patients from a cohort of 80 patients treated with infliximab. 1 Two patients showed severe reactivation, 1 of whom died. Based on the American Association for the Study of Liver Disease (AASLD) and European guidelines, 2,3 pree

Early indicators of prognosis in fulmina

Early indicators of prognosis in fulminant hepatic failure: An assessment of the Model for End-Stage Liver Disease (MELD) and King's College Hospital Criteria

✍ Radha K. Dhiman; Sanjay Jain; Uma Maheshwari; Ashish Bhalla; Navneet Sharma; Jas 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 193 KB 👁 1 views

While King's Hospital Criteria (KCH) criteria are used worldwide, the Model for End-Stage Liver Disease (MELD) is a more recently developed scoring system that has been validated as an independent predictor of patient survival in conditions for liver transplantation (LT). The aim of the present stud